7Baggers

We provide you with 20 years of free, institutional-grade data for SLDB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SLDB. Explore the full financial landscape of SLDB stock.

Reported DateCIKTickerType
2024-03-131707502SLDB10-KUrl
2023-11-081707502SLDB10-QUrl
2023-08-141707502SLDB10-QUrl
2023-05-111707502SLDB10-QUrl
2023-03-231707502SLDB10-KUrl
2022-11-101707502SLDB10-QUrl
2022-08-111707502SLDB10-QUrl
2022-04-271707502SLDB10-QUrl
2022-03-141707502SLDB10-KUrl
2021-11-031707502SLDB10-QUrl
2021-08-161707502SLDB10-QUrl
2021-05-141707502SLDB10-QUrl
2021-03-151707502SLDB10-KUrl
2020-11-051707502SLDB10-QUrl
2020-08-061707502SLDB10-QUrl
2020-05-071707502SLDB10-QUrl
2020-03-121707502SLDB10-KUrl
2019-11-121707502SLDB10-QUrl
2019-08-141707502SLDB10-QUrl
2019-05-131707502SLDB10-QUrl
2019-03-131707502SLDB10-KUrl
2018-11-131707502SLDB10-QUrl
2018-08-101707502SLDB10-QUrl
2018-05-101707502SLDB10-QUrl
2018-03-291707502SLDB10-KUrl

Solid Biosciences Inc
(NASDAQ:SLDB) 

SLDB stock logo

Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expre...

Founded: 2013
Full Time Employees: 121
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic

Share this website to your friends
The information provided in this report about SLDB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.